GATA2 methylation and FGFR3 mutation predict progression in BCG-treated high-risk non-muscle-invasive bladder cancer

被引：0
|
作者：
Olislagers, M. [1 ]
De Jong, F. C. [1 ]
Van Etten, V. M. J. [1 ]
Kan, T. W. [1 ]
Zuiverloon, T. C. M. [1 ]
机构：
[1] Erasmus MC, Dept Urol, Rotterdam, Netherlands
来源：
EUROPEAN UROLOGY | 2023年 / 83卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学]; R69 [泌尿科学（泌尿生殖系疾病）];
学科分类号：
1002 ; 100201 ;
摘要：
A0281
引用
收藏
页码：S405 / S406
页数：2
相关论文
共 50 条
  • [11] Performance of the EORTC and CUETO Models to Predict Recurrence and Progression in High-risk Non-muscle-invasive Bladder Cancer Patients
    Paztr, Yasar
    Esmeray, Abdullah
    Gelmis, Mucahit
    Caglar, Ufuk
    Ozgor, Faruk
    Sarilar, Omer
    Akbulut, Fatih
    UROLOGY JOURNAL, 2024, 21 (03) : 169 - 174
  • [12] Tumor size and T stage correlate independently with recurrence and progression in high-risk non-muscle-invasive bladder cancer patients treated with adjuvant BCG
    Zachos, Ioannis
    Tzortzis, Vasileios
    Mitrakas, Lampros
    Samarinas, Michael
    Karatzas, Anastasios
    Gravas, Stavros
    Vandoros, Gerasimos P.
    Melekos, Michael D.
    Papavassiliou, Athanasios G.
    TUMOR BIOLOGY, 2014, 35 (05) : 4185 - 4189
  • [13] Novel immunotherapeutic options for BCG-unresponsive high-risk non-muscle-invasive bladder cancer
    Hannouneh, Zein Alabdin
    Hijazi, Amjad
    Alsaleem, Alaa Aldeen
    Hami, Siwan
    Kheyrbek, Nina
    Tanous, Fadi
    Khaddour, Karam
    Abbas, Abdulfattah
    Alshehabi, Zuheir
    CANCER MEDICINE, 2023, 12 (24): : 21944 - 21968
  • [14] Outcomes of BCG vs upfront radical cystectomy for high-risk non-muscle-invasive bladder cancer
    Scilipoti, Pietro
    Longoni, Mattia
    de Angelis, Mario
    Zaurito, Paolo
    Slusarczyk, Aleksander
    Soria, Francesco
    Pradere, Benjamin
    Krajewski, Wojciech
    D'Andrea, David
    Mari, Andrea
    Del Giudice, Francesco
    Pichler, Renate
    Subiela, Jose Daniel
    Marcq, Gautier
    Gallioli, Andrea
    Afferi, Luca
    Mastroianni, Riccardo
    Simone, Giuseppe
    Albisinni, Simone
    Mertens, Laura S.
    Laukhtina, Ekaterina
    Oberneder, Katharina
    Elena, Jose Luis Rodriguez
    Aranda, Javier
    Puentedura, Alfonso Lafuente
    Velasco, Jorge Cano
    Contieri, Roberto
    Hurle, Rodolfo
    Mori, Keiichiro
    Radziszewski, Piotr
    Shariat, Shahrokh F.
    Gontero, Paolo
    Necchi, Andrea
    Roupret, Morgan
    Montorsi, Francesco
    Salonia, Andrea
    Briganti, Alberto
    Moschini, Marco
    EAU YAU
    Urothelial Carcinoma Working Grp
    BJU INTERNATIONAL, 2025,
  • [15] High-Risk Non-Muscle-Invasive Bladder Cancer—Therapy Options During Intravesical BCG Shortage
    Rajan Veeratterapillay
    Rakesh Heer
    Mark I. Johnson
    Raj Persad
    Christian Bach
    Current Urology Reports, 2016, 17
  • [16] Pembrolizumab monotherapy for high-risk, non-muscle-invasive bladder cancer
    Rentsch, Cyrill A.
    Hayoz, Stefanie
    Cathomas, Richard
    LANCET ONCOLOGY, 2021, 22 (09): : E379 - E379
  • [17] OPTIMALIZATION OF NON-MUSCLE-INVASIVE BLADDER CANCER RECURRENCE DETECTION USING A URINE-BASED FGFR3 MUTATION ASSAY
    Zuiverloon, T. C. M.
    Tjin, S. S.
    Busstra, M.
    Bangma, C. H.
    Boeve, E. R.
    Zwarthoff, E. C.
    EUROPEAN UROLOGY SUPPLEMENTS, 2011, 10 (02) : 197 - 197
  • [18] TP53 codon 72 polymorphism is associated with FGFR3 and RAS mutation in non-muscle-invasive bladder cancer
    Kawahara, Takashi
    Kojima, Takahiro
    Kandori, Shuya
    Kurobe, Masahiro
    Yoshino, Takayuki
    Kimura, Tomokazu
    Nagumo, Yoshiyuki
    Ishituka, Ryutaro
    Mitsuzuka, Koji
    Narita, Shintaro
    Kobayashi, Takashi
    Matsui, Yoshiyuki
    Ogawa, Osamu
    Sugimoto, Mikio
    Miyazaki, Jun
    Nishiyama, Hiroyuki
    PLOS ONE, 2019, 14 (08):
  • [19] Role of the FGFR3 gene mutation status in predicting progression of non- muscle-invasive bladder cancer
    Rolevich, A. I.
    Smal, M. P.
    Krasnyi, S. A.
    Goncharova, R. I.
    ONKOUROLOGIYA, 2015, 11 (03): : 62 - 70
  • [20] Hypermethylation of GATA2 is validated as a marker of progression in non-muscle invasive bladder cancer
    van Kessel, Kim E. M.
    van der Keur, Kirstin A.
    Dyrskjot, Lars
    Algaba, Ferran
    Welvaart, Naeromy
    Beukers, Willemien
    Segersten, Ulrika
    Keck, Bastian
    Maurer, Tobias
    Simic, Tatjana
    Horstmann, Marcus
    Boormans, Joost L.
    Real, Francisco X.
    Malats, Nuria
    Malmstronn, Per-Uno
    Orntoft, Torben F.
    Zwarthoff, Ellen C.
    CANCER RESEARCH, 2016, 76
12345